Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
| 8/6/2024 | $100.00 | Buy | Stifel |
| 5/30/2024 | $87.00 | Neutral | Goldman |
| 2/15/2024 | $100.00 | Buy | HSBC Securities |
| 2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
This is GE HealthCare's first appearance on the list, marking a significant milestone as an independent company GE HealthCare (NASDAQ:GEHC) has been named to 2025 Fortune World's Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets. Being named to Fortune World's Most Admired Companies™ list for the first time, two years after becoming an independent company, is a testament to GE HealthCare's progress agai
Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence GE HealthCare (NASDAQ:GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and
New joint research program combines UCSF's advanced clinical and research teams with GE HealthCare's technical and engineering expertise to develop solutions that directly impact patient care. The collaboration aims to address two of the most prevalent disease states worldwide, neurodegenerative disease and cancer, by increasing accessibility of imaging, driving clinical impact and translating techniques to diagnose and treat these critical illnesses. University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare today announced the launch of a Care Innovation Hub, a joint research collaboration that aims to address meaningful clinical c
Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)